Dublin - Research and Markets has announced the addition of the "Algeria Pharmaceuticals and Healthcare Report Q2 2009" report to their offering.
Gradual liberalisation of Algeria's economy over the past decades has resulted in the country emerging as one of the more promising new markets. In terms of opportunities for the pharmaceutical industry, however, the country is judged as having one of the most challenging operating environments out of the 17 key markets surveyed by BMI's Q209 Business Environment Rankings matrix in the Middle East and Africa (MEA) region. Main criticisms include certain shortcoming of its regulatory and intellectual property (IP) regimes, which are biased against local - overwhelmingly generic - producers. Nevertheless, although per capita spending on healthcare and drugs continues to lag behind some of its MENA peers, Algeria's position as a major oil and gas exporter will play a significant role in healthcare system modernisation over the coming years.
In the forecast period, Algerian pharmaceutical expenditure at consumer prices is forecast to rise at a compound annual growth rate (CAGR) of 6.16% in local currency terms, with the market value increasing from DZD158.98bn (US$2.35bn) in 2008 to DZD214.41bn (US$3.02bn) in 2013. This rate of growth is roughly in line with a number of other regional markets, with faster value development severely hampered by the emphasis on the use of cheaper, generic medicines, both imported and produced locally.
No comments:
Post a Comment